MCL Literature Feed

In untreated mantle cell lymphoma, adding acalabrutinib to bendamustine-rituximab significantly improves progression-free survival with manageable toxicity, offering a potentially safer chemoimmunotherapy combination than ibrutinib-based regimens.

This review outlines key clinical strategies for patient selection, toxicity management, and overcoming resistance to maximize the efficacy and safety of CAR-T therapy in relapsed/refractory MCL.

This review summarizes recent phase II/III trial data supporting the integration of covalent BTK inhibitors into frontline MCL therapy, proposing new treatment algorithms for this setting.

This review outlines emerging treatment strategies for relapsed/refractory MCL patients who progress after CAR-T therapy, addressing a significant and growing unmet clinical need in this setting.

A four-decade analysis demonstrates significant, gradual overall survival improvement in MCL, validating the cumulative clinical impact of evolving therapies from chemotherapy to novel agents and transplant.

M2-polarized macrophages drive ibrutinib resistance via the CXCL5/CXCR2 axis; a CXCR2 inhibitor re-sensitizes MCL cells, suggesting a novel combination therapy to overcome BTKi resistance.

This organic chemistry paper describes a method for synthesizing complex molecules and has no direct relevance to mantle cell lymphoma clinical research, treatment, or biology.

A case of benign BCL-6-positive cutaneous mantle zone hyperplasia mimics cutaneous lymphoma, highlighting that cyclin-D1 staining remains essential to differentiate this benign entity from cutaneous mantle cell lymphoma.

This review of FDA-approved covalent inhibitors highlights the foundational role of BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) in MCL, which established this successful drug development strategy.

IGH/IGK gene rearrangement analysis improves diagnostic accuracy for B-cell lymphomas, with co-occurring IGH and IGK rearrangements being a characteristic feature of mantle cell lymphoma.

The m6A writer METTL3 promotes MCL progression by degrading Ambra1 mRNA via the reader YTHDF2, identifying a novel, potentially targetable therapeutic axis for mantle cell lymphoma.

A case report highlights chylothorax as a rare clinical presentation of mantle cell lymphoma, underscoring the need to consider malignancy in the differential diagnosis of this condition.

Polypharmacy independently predicts worse survival, hospitalization, and infection rates in lymphoid cancers, highlighting the critical need for medication reconciliation and management in the MCL population.

This meta-analysis in TP53-mutated MCL supports targeted therapy frontline and CAR-T or transplant in relapse, but confirms poor long-term survival, highlighting the need for novel approaches.

Real-world data on the ibrutinib, lenalidomide, and rituximab triplet in relapsed/refractory non-Hodgkin lymphoma provides practical insights into the efficacy and safety of this chemotherapy-free regimen.

A US claims analysis shows MCL treatment costs increase substantially with each line of therapy, driven by hospitalizations, underscoring the economic need for more effective, durable frontline regimens.

This case report of sequential follicular lymphoma, MCL, and CML highlights the long-term risk of subsequent malignancies and severe infections (COVID-19-induced HLH) following repeated immunochemotherapy.

This case report of a rectal plasmacytoma misdiagnosed as MCL highlights a critical diagnostic pitfall, emphasizing the need for thorough pathological evaluation to prevent incorrect lymphoma-directed therapy.

This case report describes a rare, rapid progression from acute myopericarditis to pericardial calcification after initial CHOP chemotherapy, highlighting a severe, early-onset cardiotoxicity risk with this regimen.

New prognostic scores, AMOS and AMES, were developed for Indian MCL patients, showing better predictive accuracy than MIPI using simple clinical factors for improved risk stratification.

This first reported case of composite MCL and T-cell prolymphocytic leukemia highlights the diagnostic challenge of co-existing lymphoid malignancies, where an indolent T-PLL clone was present for years before diagnosis.

This MZL case identifies BTK C481S and PLCG2 D334H co-mutations driving zanubrutinib resistance, a mechanism highly relevant to BTKi failure and subsequent treatment strategies in relapsed MCL.

This study identifies predictors of outcome for covalent BTKi therapy in relapsed/refractory TP53-mutant MCL, helping to risk-stratify patients and guide subsequent treatment decisions.

The MCL35 gene expression assay identifies high-risk older patients who do not benefit from adding ibrutinib to bendamustine-rituximab, mandating alternative frontline strategies for this molecularly-defined subgroup.

This review outlines strategies like non-viral vectors, allogeneic products, and point-of-care manufacturing to reduce CAR-T therapy costs, potentially increasing access for relapsed/refractory MCL patients.

M2-like macrophages secrete IL-1 receptor antagonist (IL-1ra), impairing CAR-T19 function in MCL, suggesting targeting the IL-1 pathway could overcome this novel resistance mechanism.

The novel metabolism-targeting agent KAT/3BP demonstrates preclinical activity in aggressive B-cell lymphomas, introducing a new therapeutic class with potential future applications for treating MCL.

This phase 1 study shows the novel chemo-free triplet of magrolimab (anti-CD47), obinutuzumab, and venetoclax is a potential strategy for relapsed/refractory B-cell lymphomas, including MCL.

The combination of ibrutinib and venetoclax improves progression-free survival in relapsed/refractory MCL, establishing a highly effective, chemotherapy-free regimen for this difficult-to-treat population.

This preclinical study demonstrates potent anti-MCL activity with a triple combination of bendamustine, acalabrutinib, and venetoclax, providing a strong rationale for future clinical trials.